Expression patterns in PBTs are mostly heterogenous with some TAAs more robustly expressed across tumor subtypes (GD2, B7-H3, IL13Rα2), while other targets have variable expression frequencies and intensities (HER2, EphA2, EGFRvIII). Here, EPHA2 is linked to neoplasm.